The introduction of anti-estrogen (e.g., tamoxifen) and anti-HER2 (e.g., Herceptin)-based adjuvant treatments for ER+ and HER2+ BC, respectively, in combination with mastectomy or breast-saving surgery, have improved survival by about 30% in the past three decades [14]. Here, ESR1 is linked to breast cancer.